JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice - read this article along with other careers information, tips and advice on BioSpace
Published: Apr 23, 2021
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) CareDx, Inc., Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced experts will present its latest heart research, which was accepted at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, set to take place between April 24-28, 2021.
CareDx’s offerings are showcased through 22 abstracts throughout the ISHLT program. These data selected by the ISHLT organizers, will be presented by prominent thought leaders, highlighting the continued leadership in the cardiothoracic space. Additionally, a CareDx symposium will spotlight leaders in the field of heart and lung transplantation delivering cutting edge content on HeartCare, AlloMap